3 papers in the library · 27 citations · publishing 2025
Clinical Pharmacokinetics January 1, 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. 20 citations
The pharmacokinetic parameters of psilocin are consistent across different studies. This finding may help guide the further clinical development of psilocybin-based therapies.
Clinical and Translational Science May 1, 2025 Katelijne V. van der Heijden, Rob G J A Zuiker, Marije E. Otto et al. 7 citations
Intravenous DMT administered as a 30-second bolus followed by a 6-hour infusion, reaching peak blood concentrations around 35 ng/mL, is safe in healthy volunteers. No serious adverse events occurred; all side effects were mild and self-limiting. Vital signs, electrocardiography, and measures of suicidality or psychopathology showed no significant abnormalities. Mild psychedelic effects were accompanied by temporary decreases in sustained attention, postural stability, and occipital alpha brain wave power at the highest dose. Moderate variability in drug levels between individuals was observed. These findings support further testing of prolonged DMT infusion as a potential treatment to promote neuroplasticity in stroke recovery.
Clinical Pharmacokinetics February 21, 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. correction
No Summary